From Diagnostic Mimicry to Diagnostic Clarity Authors: Ibrahim El-Battrawy, Ibrahim Akin, Muchtiar Khan, Loek van Heerebeek, Nazha Hamdani Published: 2026 ABSTRACT Graphical AbstractKey words: diagnostic, genetic testing, monitoring, pharmacology, sudden cardiac death, ventricular fibrillation Refining the Diagnosis of Idiopathic Ventricular Fibrillation Sudden cardiac death (SCD) remains one of the leading causes of cardiovascular mortality worldwide, accounting for approximately 4 and 5 million deaths annually. While ischemic heart disease predominates in older populations, inherited cardiomyopathies and channelopathies represent a major cause in young individuals without structural heart disease.1 Distinguishing between these entities is critical, as management, family screening, and prognosis differ substantially. Inherited cardiomyopathies are typically characterized by structural abnormalities detectable on cardiac imaging. In contrast, inherited channelopathies are primarily electrical disorders, manifesting as electrocardiographic (ECG) abnormalities either at baseline or under pharmacological or physiological provocation. However, despite a comprehensive evaluation, a subset of patients remain without an identifiable substrate. In such cases, the diagnosis of idiopathic ventricular fibrillation (IVF) is made by definition, a diagnosis of exclusion. The present case in this issue of JACC: Case Reports2 elegantly illustrates the dynamic and often nonlinear diagnostic evolution from a presumed channelopathy to IVF, underscoring the importance of serial reassessment and prolonged rhythm monitoring. A structured and stepwise diagnostic framework for survivors of unexplained sudden cardiac arrest is summarized in Figure 1. Structured Diagnostic Algorithm for Survivors of Unexplained Sudden Cardiac Arrest Diagnostic Evaluation After Aborted SCD A systematic, stepwise diagnostic approach is mandatory following an aborted SCD. Initial evaluation should include a 12-lead ECG, transthoracic echocardiography, laboratory testing to exclude reversible causes (electrolyte imbalance, ischemia, metabolic disturbances), and careful medication review. Importantly, ECG abnormalities observed in the acute setting may reflect transient factors such as resuscitation effects, autonomic instability, drug exposure, or therapeutic hypothermia.3 In the present case, the initial ECG was normal. A subsequent ECG recorded during torsades de pointes (TdP) demonstrated QTc prolongation. However, serial ECGs failed to confirm a persistently prolonged QT interval. This observation highlights a crucial principle: repeating ECG assessment after stabilization and elimination of reversible triggers is essential to avoid misclassifying transient repolarization changes as congenital long QT syndrome (LQTS). Serial evaluation can therefore serve 2 purposes: either confirming a concealed phenotype or preventing an erroneous lifelong diagnosis. The Role and Limitations of Genetic Testing Genetic testing is a cornerstone in the evaluation of young survivors of SCD without structural abnormalities.3 Targeted gene panels covering major channelopathy- and cardiomyopathy-associated genes are widely used and were appropriately employed in this case. A negative genetic panel, however, must be interpreted cautiously. Up to 20% to 30% of clinically robust LQTS cases remain genotype-negative despite a strong clinical phenotype, reflecting the current limitations of genetic testing and the possibility of undiscovered genes or regulatory variants.4 Moreover, current panels may fail to detect regulatory variants, deep intronic mutations, polygenic contributions, or yet-undiscovered genes. Therefore, a negative test does not exclude inherited arrhythmogenic disease but should prompt re-evaluation of the phenotype in parallel with ongoing surveillance. Short QT syndrome, for example, remains under-recognized, and recent identification of additional gene associations has broadened diagnostic considerations.5 These developments reinforce that IVF may represent either a truly idiopathic entity or an incompletely characterized genetic substrate beyond current diagnostic resolution. Family Screening and Risk Stratification A structured three-generation family history and cascade screening remain essential components of postarrest evaluation. Even in the absence of reported family history, inherited disease cannot be excluded due to incomplete penetrance or de novo mutations. ECG screening of first-degree relatives may uncover subclinical phenotypes and inform risk stratification. In this case, no family history of SCD was documented. Device Therapy: Cornerstone of Secondary Prevention Following aborted SCD, implantation of an implantable cardioverter-defibrillator (ICD) is strongly recommended for secondary prevention. ICD therapy remains the only intervention proven to reduce mortality in this setting. In young patients without pacing indications, the subcutaneous ICD has emerged as an attractive alternative to transvenous systems, avoiding intravascular leads and potentially reducing long-term lead-related complications.6 Device selection should be individualized, considering arrhythmia burden, pacing requirements, and patient-specific factors. In the present case, ICD implantation was unequivocally validated by subsequent appropriate therapy. Pharmacological Strategy in the Absence of a Defined Genotype Pharmacologic management after SCD related to inherited channelopathy depends on the suspected underlying mechanism. In LQTS, nonselective beta-blockers are first-line therapy, while catecholaminergic polymorphic ventricular tachycardia may require beta-blockers with or without flecainide. Hydroquinidine has shown optimistic findings in a limited number of short QT syndrome patients.3 In IVF, no genotype-specific guidelines exist. Treatment is therefore pragmatic and focused on suppressing ventricular arrhythmias and preventing recurrent ICD shocks. In addition, quinidine has emerged as a potentially effective pharmacological therapy in selected patients with IVF, particularly when arrhythmias are triggered by short-coupled premature ventricular complexes (PVCs) originating from the Purkinje network. Quinidine inhibits multiple potassium currents, including the transient outward potassium current (Ito), thereby prolonging ventricular refractoriness and suppressing ventricular fibrillation triggers. Clinical studies have demonstrated that quinidine can reduce recurrent ventricular fibrillation episodes and ICD shocks in IVF patients, especially when catheter ablation is not feasible or when Purkinje triggers cannot be reliably mapped.7 The combination of nadolol and amiodarone in this case represents an aggressive antiarrhythmic strategy. Beta-blockade may attenuate adrenergic triggers, while amiodarone exerts multichannel effects that prolong refractoriness and reduce ventricular arrhythmia susceptibility. Such combination therapy is typically reserved for patients perceived to be at high risk of recurrence or electrical storm, and long-term toxicity monitoring is essential. Mechanistic Insights: The Decisive Role of Prolonged Monitoring A defining feature of this case was the use of implantable loop recorder data to clarify the arrhythmic mechanism. While the initial event resembled TdP, implantable loop recorder interrogation demonstrated abrupt-onset ventricular fibrillation initiated by short-coupled PVCs, without preceding bradycardia or QT prolongation. This distinction is clinically critical. Classical TdP in LQTS is often pause-dependent and driven by early afterdepolarizations. In contrast, IVF frequently arises from short-coupled PVCs, often originating within the Purkinje network. Purkinje-mediated triggers have been well described in IVF,7 and catheter ablation targeting these foci can reduce recurrence in selected patients. However, mapping may be challenging when PVC burden is low or intermittent, as illustrated here. This case therefore emphasizes that long-term rhythm monitoring is not merely confirmatory but can fundamentally redefine diagnosis by revealing the dominant electrophysiological mechanism. The Heart–Brain Interface: When Arrhythmia Mimics Epilepsy Seizure-like activity is a recognized presentation of malignant ventricular arrhythmias. Cerebral hypoperfusion during ventricular fibrillation may produce convulsive syncope, frequently leading to initial neurological misclassification. Simultaneous electroencephalogram and telemetry recording in this case was pivotal in distinguishing arrhythmic convulsive syncope from primary epilepsy. This highlights the importance of integrated cardiological and neurological evaluation in young patients presenting with unexplained seizure-like events. Conclusions IVF remains a diagnosis of exclusion requiring systematic evaluation, genetic testing, and prolonged rhythm monitoring. This case demonstrates how a careful reassessment can prevent misclassification and ensure appropriate management. Until emerging genetic and mechanistic insights further refine our understanding, vigilant follow-up and disciplined clinical reasoning remain essential. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References